KMT2A and leukemia: Several clinical studies are recruiting to assess the safety and efficacy of menin inhibitors such as SNDX-5613 and KO-539 on leukemia with MLL-rearrangement or NPM1 mutation (NCT04067336, NCT04065399, NCT04811560, NCT04752163, Table 2).